NewsJŠK advised TESCAN ORSAY HOLDING a.s. on the sale of a majority stake to Carlyle, a global private equity fund

TESCAN enables nanoscale investigation and analysis within the geosciences, material science, life sciences and semiconductor industries. The company has a 30-year history of developing innovative electron microscopy, micro-computed tomography, and related software solutions for customers in research and industry worldwide. For example, TESCAN’s TENSOR is the first 4D-scanning transmission electron microscope (4D-STEM) built from the ground up for a totally new level of performance and user experience. As a result, TESCAN has earned a leading position in micro- and nanotechnology. TESCAN is headquartered in Brno, Czech Republic, and employs more than 750 people in 14 sites around the world.

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With USD 369 billion of assets under management as of 30 September 2022, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,100 people in 29 offices across five continents.

The JŠK transaction team was led by partner Tomáš Doležil on the sell side in cooperation with senior associates Klára Šmídová, Patrik Müller and Lucia Regecová together with junior associates Marek Pume and Jan Koprnický.

“It was a great honour to support the sellers in this transaction and I am confident that we will successfully complete the transaction,” Tomáš Doležil said. “The sellers’ structure was a factor that multiplied the complexity of the transaction. I am really glad that we were able to bring all the sellers successfully to completion.”

Freeths supported JŠK and the clients in relation to the English law aspects of the transaction¨.